Gorelik E
Cancer Res. 1987 Feb 1;47(3):809-15.
The effect of anticoagulant drugs on formation of experimental tumor metastases after i.v. inoculation of BL6 melanoma or Lewis lung carcinoma (3LL) cells was studied in mice with stimulated or depressed natural killer (NK) cell activity. When mice were treated with anticoagulants (warfarin or heparin) or when NK cell activity was stimulated by polyinosinic-polycytidylic acid, significant antimetastatic effects were observed; these effects were substantially augmented when the treatments were combined. However, when NK reactivity of mice was suppressed by anti-asialo GM1 serum or cyclophosphamide, the antimetastatic effects of warfarin and heparin were diminished or completely abrogated. In some experiments, the anticoagulants had a partial effect in mice treated with cyclophosphamide or anti-asialo GM1 serum and reduced at least to control levels the number of metastases in these mice. This limited antimetastatic effect of the anticoagulants was mostly due to the action of residual NK cells, since it was completely abrogated in mice whose NK cell activity was more completely suppressed by two injections of anti-asialo GM1 serum. In addition, the low NK reactivity of 3-week-old C57BL/6 or beige mice was sufficient to support the antimetastatic effects of the anticoagulants, effects that completely disappeared after these mice were treated with anti-asialo GM1 serum. Augmentation or abrogation of the antimetastatic effects of heparin after polyinosinic-polycytidylic acid or anti-asialo GM1 treatments, respectively, was observed in athymic nude and allogeneic BALB/c mice that received i.v. injections of B16F1 melanoma cells, indicating that the antimetastatic effects of anticoagulants depend on the presence of active NK rather than T-cells. Furthermore, adoptive transfer of NK-competent but not NK-depleted syngeneic spleen cells restored the antimetastatic effect of heparin in cyclophosphamide-treated mice. Warfarin treatment increased the elimination of radiolabeled BL6 melanoma cells from the lungs of normal mice, and the rate of tumor cell elimination was further potentiated when NK cell activity was stimulated by polyinosinic-polycytidylic acid. In contrast, after anti-asialo GM1 treatment, warfarin had no effect on the survival of i.v. administered tumor cells. Covering of YAC-1 or 3LL tumor cells with fibrin after in vitro exposure with fibrinogen and thrombin substantially protected them from the in vitro cytotoxic action of NK or lymphokine-activated killer cells.(ABSTRACT TRUNCATED AT 400 WORDS)
在自然杀伤(NK)细胞活性受到刺激或抑制的小鼠中,研究了抗凝药物对静脉注射BL6黑色素瘤或Lewis肺癌(3LL)细胞后实验性肿瘤转移形成的影响。当用抗凝剂(华法林或肝素)治疗小鼠,或用聚肌苷酸-聚胞苷酸刺激NK细胞活性时,观察到显著的抗转移作用;当联合治疗时,这些作用显著增强。然而,当用抗唾液酸GM1血清或环磷酰胺抑制小鼠的NK反应性时,华法林和肝素的抗转移作用减弱或完全消除。在一些实验中,抗凝剂对用环磷酰胺或抗唾液酸GM1血清治疗的小鼠有部分作用,并将这些小鼠体内的转移灶数量至少降低到对照水平。抗凝剂这种有限的抗转移作用主要归因于残余NK细胞的作用,因为在通过两次注射抗唾液酸GM1血清更完全抑制NK细胞活性的小鼠中,这种作用完全消除。此外,3周龄C57BL/6或米色小鼠的低NK反应性足以支持抗凝剂的抗转移作用,在用抗唾液酸GM1血清治疗这些小鼠后,这些作用完全消失。在用静脉注射B16F1黑色素瘤细胞的无胸腺裸鼠和同种异体BALB/c小鼠中,分别观察到聚肌苷酸-聚胞苷酸或抗唾液酸GM1处理后肝素抗转移作用的增强或消除,这表明抗凝剂的抗转移作用取决于活性NK细胞而非T细胞的存在。此外,具有NK活性但未被耗尽的同基因脾细胞的过继转移恢复了环磷酰胺处理小鼠中肝素的抗转移作用。华法林治疗增加了正常小鼠肺部放射性标记的BL6黑色素瘤细胞的清除,当用聚肌苷酸-聚胞苷酸刺激NK细胞活性时,肿瘤细胞的清除率进一步提高。相反,在抗唾液酸GM1处理后,华法林对静脉注射的肿瘤细胞存活没有影响。在体外将YAC-1或3LL肿瘤细胞与纤维蛋白原和凝血酶一起孵育后,用纤维蛋白覆盖可显著保护它们免受NK或淋巴因子激活的杀伤细胞的体外细胞毒性作用。(摘要截短于400字)